glp 1 agonists for obesity Weight Reduction with GLP-1 and Paths Discontinuation While Maintaining Weight Loss Harnessing GLP-1 Receptor Agonists for

If your plan includes coverage for weight management medications, we will continue to leverage aggressive formulary and UM strategies to help ensure cost-effective, clinically appropriate coverage consistent with Food and Drug Administration (FDA)-approved labeling and clinical compendia

21,23 Managing other preexisting GI conditions, such as gastroesophageal reflux disease or constipation, before initiating GLP-1 RAs can reduce the likelihood of severe GI AEs and improve overall tolerability

In July 2024, Amylyx Pharmaceuticals announced the acquisition of avexitide from Eiger BioPharmaceuticals

Despite these advances, several controversies remain unresolved

Cardiovasc Endocrinol Metab 2023

average baseline Body Mass Index (BMI) ranged from 24.1 to 45.1 kg/m 2 , with a median of 33.9 kg/m 2